Dasatinib
| Authors | |
|---|---|
| Year of publication | 2007 |
| Type | Article in Periodical |
| Magazine / Source | Remedia |
| MU Faculty or unit | |
| Citation | |
| Web | http://www.remedia.cz/1096.magarticleprintversion.ashx |
| Field | Oncology and hematology |
| Keywords | chronic myeloid leukemia; dasatinib; imatinib; resistance |
| Description | The therapy of chronic myeloid leukemia (CML) has changed significantly over the last decade. A great breakthrough in CML therapy was the discovery of imatinib, a BCR-ABL thyrosine kinase inhibitor. Despite the efficacy of imatinib some CML patients are either resistant or intolerant to treatment with this agent. Dasatinib (formerly BMS-354825), a newly marketed BCR-ABL, Src and other kinase inhibitor, can be prescribed mainly to these patients. Dasatinib is able to induce 87 % of complete hematological remissions and 28 % of complete cytogenetic remissions in imatinib resistant chronic CML patients and even 97 % and 64 % of remissions, respectively, in imatinib intolerant chronic CML patients. Dasatinib is also effective in the treatment of patients with accelerated CML, blastic CML and Ph-positive acute lymphoblastic leukemia. |